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Abstract
Objectives: Soluble factors released by Bifidobacterium breve C50 (Bb) alleviate the secretion of pro-inflammatory cytokines
by immune cells, but their effect on intestinal epithelium remains elusive. To decipher the mechanisms accounting for the
cross-talk between bacteria/soluble factors and intestinal epithelium, we measured the capacity of the bacteria, its
conditioned medium (Bb-CM) and other Gram(+) commensal bacteria to dampen inflammatory chemokine secretion.
Methods: TNFa-induced chemokine (CXCL8) secretion and alteration of NF-kB and AP-1 signalling pathways by Bb were
studied by EMSA, confocal microscopy and western blotting. Anti-inflammatory capacity was also tested in vivo in a model
of TNBS-induced colitis in mice.
Results: Bb and Bb-CM, but not other commensal bacteria, induced a time and dose-dependent inhibition of CXCL8
secretion by epithelial cells driven by both AP-1 and NF-kB transcription pathways and implying decreased phosphorylation
of p38-MAPK and IkB-a molecules. In TNBS-induced colitis in mice, Bb-CM decreased the colitis score and inflammatory
cytokine expression, an effect reproduced by dendritic cell conditioning with Bb-CM.
Conclusions: Bb and secreted soluble factors contribute positively to intestinal homeostasis by attenuating chemokine
production. The results indicate that Bb down regulate inflammation at the epithelial level by inhibiting phosphorylations
involved in inflammatory processes and by protective conditioning of dendritic cells.
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Introduction
Intestinal homeostasis depends in part on the equilibrium
between absorption (nutrients, Na+ ions), secretion (chloride ions,
IgA, mucus, cytokines) and barrier function of the digestive
epithelium. Disturbance of intestinal homeostasis results in chronic
inflammation and release of pro-inflammatory cytokines resulting
in diarrhoea and injury to the gut. The intestinal epithelium
constitutes a major interface between intestinal contents, including
bacteria, and the internal milieu, providing an important
contribution to the regulation of intestinal homeostasis. Probiotics
are specific bacterial strains capable of stimulating protective
immune responses in physiological conditions[1] but which also
dampen inflammation in some inflammatory bowel diseases [2].
One of the main functions of the intestinal epithelium is to
regulate the ion transport controlling the balance between
absorption and secretion of fluid. Intestinal epithelial cells (IECs)
are considered an integral part of the innate immune system,
constituting important targets for bacteria and cytokines. Their
polarization contributes to the fine regulation of intestinal
homeostasis [3–5]. In the physiological steady-state, minimal
stimulation of IECs by luminal bacteria occurs at the apical pole.
Indeed, pathogen recognition receptors (PRRs) are functionally
silenced in the healthy intestine due to their redistribution to
internal or basolateral compartments or to the delivery of
inhibitory signals [6,7]. In contrast, in pathology, recognition of
invading bacteria promotes signalling cascades of pro-inflamma-
tory cytokines and chemokines[8] and the recruitment/activation
of mucosal immune cells. In this context, selected strains of
probiotic bacteria have been proposed as tools in the prevention or
treatment of inflammatory bowel diseases, especially in ulcerative
colitis [2]. Mechanisms sustaining such beneficial effects have been
partially identified in vitro[9,10] and depend mainly upon
alleviation of NF-kB-dependent transcriptional activity. We have
already demonstrated that soluble factors released by the probiotic
bacteria Bifidobacterium breve (Bb) C50 can down-regulate the
production of inflammatory cytokines by immune cells [11], with
these factors maintaining their inhibitory activity after crossing an
epithelial barrier. Herein, we demonstrated the inhibitory effect of
Bb soluble factors on epithelial signalling pathways leading to
chemokine secretion in inflammation and confirmed their
alleviating effect in a mouse model of colitis.
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Methods
Bacteria and conditioned media
Bifidobacterium breve (Bb) C50 was purchased from Bledina-SA
(Steenvoorde, France). Bifidobacterium breve 15698 and Lactobacillus
rhamnosus 10893 were purchased from ATCC, and Eubacterium
rectale L15, isolated from a dominant human microflora, was
provided by G. Corthier (INRA, Jouy en Josas, France). Bacteria
cultured in BH medium were seeded for 24 hours in DMEM
(Gibco) containing 10% fetal calf serum (FCS) and 2% inulin. Bb-
conditioned-media corresponding to 36108 CFU/ml were
prepared by ultracentrifugation (100,000 g, 1 h) and adjusted
to pH 7.0. As demonstrated with immune cells, active soluble
factors in Bb-conditioned media are less than 3 kD [11].
Conditioned media were thus ultrafiltrated on CentriplusH YM-
3 (Millipore) and sterilized. This fraction constituted the Bb-
conditioned medium (Bb-CM), also noted as ‘‘soluble factors’’ in
this study.
Effect of Bb, Bb-CM or commensal bacteria on chemokine
secretion pathways in intestinal epithelial cells
HT29-19A cells were seeded on 24-well plates (FalconH) at
26105 cells/well for 3 days. After overnight starving of FCS,
monolayers were stimulated either basolaterally with TNFa
(10 ng/ml) and/or apically with Bb-CM or Bb at increasing
multiplicity of infection (MOI: 10, 50 or 100), i.e. number of
bacteria per epithelial cell. Conditioned media were collected after
4 hours for cytokine assays.
Human cytokine antibody array and CXCL8 assay
RayBioH Human Cytokine Antibody Array V membranes
(Raybiotech Inc) were incubated with HT29-19A conditioned
media and processed according to the manufacturer’s instructions
(Scheme of the various cytokines/chemokines detected can be
found at http://www.raybiotech.com). Positive spots were ana-
lyzed with a CCD camera (Fuji LAS-1000 plus) and semi-
quantified with the Image Gauge software (Molecular Dynamics).
Figure 1. Bb and its soluble factors dampen TNFa-induced cytokine secretion in epithelial cells. A. After 4 hour-incubation of HT29-19A
cells with TNFa6Bb (MOI 100) or Bb-CM, epithelial cell supernatants were tested by the RaybioH human cytokine array V (One representative array of
two experiments). Secretion of chemokines (CXCL1, CXCL8, CCL4) and of other inflammatory molecules was inhibited in the presence of Bb and Bb-
CM as judged by densitometric analysis. B. Long lasting inhibition (up to 7 hours) of CXCL8 secretion by Bb-CM (,50%) was observed using ELISA.
n = 7, *p,0.01 vs TNFa. C–D. HT29-19A cell monolayers were treated (4 hours) from the basolateral compartment with TNFa together with Bb or
commensal bacteria (B.breve ATCC 15698, L.rhamnosus 10863, E.rectale L15) placed in the apical compartment at increasing MOI. As quantified by
ELISA, Bb dose-dependently inhibited TNFa-induced CXCL8 secretion, in contrast to other bacteria. n = 11, {p,0.0001 ; *p,0.001 vs TNFa.
doi:10.1371/journal.pone.0005184.g001
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Secretion of CXCL8 was assayed using the Duoset enzyme-
linked immunosorbent assay (ELISA) (R&D Systems).
Epithelial cell viability
As indexes of epithelial viability, we measured transepithelial
electrical resistance (R), early apoptosis and zonula occludens 1
(ZO-1) distribution.
Filter-grown HT29-19A cell monolayers were cut-out from the
insert and mounted in Ussing chambers. Potential difference (PD)
and short-circuit current (Isc) were recorded and R was calculated
according the ohm’s law.
Epithelial cell apoptosis was assessed with the monoclonal
antibody M30 CytoDEATH (Roche Diagnostics, Meylan, France)
which recognizes cleaved cytokeratin 18, a marker of early
apoptosis. A 10 min-treatment of epithelial cells with H2O2
(100 mM) was used as a positive control. Filter-grown HT29-19A
cell monolayers (CostarH clear 3460) were incubated for 4 hours
with Bb, and treated according to the manufacturer. Cells were
incubated successively with mouse monoclonal IgG2b anti-M30
(1:10) and rabbit polyclonal anti-ZO-1 (24 mg/ml, Zymed,
Clinisciences) for 60 and 30 min respectively. After washes, Cy5-
goat anti-mouse IgG (H+L) and FITC-goat anti-rabbit (Jackson
Laboratories, Immunotech, 15 mg/ml) were added for 30 min.
Cell monolayers were observed by confocal microscopy.
Activation of NF-kB and AP-1
Immunofluorescence analysis of nuclear translocation of
p65-NF-kB. HT29-19A cells were grown for 3 days in eight-
chamber slides (Lab-tek, Nunc), starved of FCS overnight and
treated for 30 min with TNFa with or without Bb-CM. After
fixation in formaldehyde 4%, cells were incubated for 90 min with
a mouse monoclonal anti-p65 antibody (2 mg/ml, Santa Cruz) and
FITC-goat anti-mouse IgG (Jackson laboratories) for 30 min.
Nuclei were labelled using TOPRO-3 (0.04 mg/ml) and cell
preparations observed using confocal microscopy.
Electrophoretic Migration Shift Assay (EMSA). HT29-
19A monolayers were treated with TNFa6bacteria for 4 hours
and nuclear extracts (3 mg) were prepared and incubated in
binding buffer with 0.35 pmol of 32P-labeled DNA probes
corresponding to the kB or AP-1 binding sites (Promega) as
previously described [12]. After 1 hour incubation, protein-DNA
complexes were resolved in a 5% polyacrylamide gel in Tris-
borate-EDTA buffer. The gel was exposed to a PhosphorImager
screen (Molecular Dynamics) and quantified with ImageQuant
software (Molecular Dynamics).
Western Blot analysis of p38 MAPK phosphorylation and
IkB-a complex. HT29-19A cell lysates (30 mg) were
fractionated on SDS-PAGE and transferred onto PVDF
membrane. Membranes were blocked and incubated with mouse
anti-phospho-p38 (2 mg/ml; Sigma-Aldrich), mouse anti-phospho-
IkB-a (Ser32/36) (1:200; Cell Signaling), rabbit polyclonal anti-
p38 (12 mg/ml; Sigma-Aldrich), rabbit polyclonal anti IkB-a
(1 mg/ml; Santa Cruz) or mouse anti-b-actin (2 mg/ml; Santa
Cruz). Appropriate HRP-conjugated secondary antibodies were
used and membranes were revealed with a CCD camera (Fuji
LAS-1000 plus).
Trinitrobenzene sulfonic acid (TNBS)-induced colitis in
mice
Animal experiments were performed in an accredited estab-
lishment (nuA59107, animal facility of the Institut Pasteur de Lille,
France) and carried out in accordance with the guidelines of
laboratory animal care published by the French Ethical committee
and the rules of the European Union Normatives (number 86/
609/EEC). Colitis was induced by intra-rectal administration of
50 ml TNBS (110 mg/kg) in 0.9% (w/v) NaCl/ethanol (50:50 v/v)
in anesthetized BALB/c mice (female, 7–8-weeks-old) as described
[13]. The colitis control group received TNBS only. The Bb i.g.
group received a daily intragastric administration of 108 CFU of
Bb in 100 ml gavage buffer 5 days before colitis induction. The Bb-
CM i.p. group received two intra-peritoneal (i.p. 200 ml) injections
of a 5-fold concentrated Bb-CM at one day intervals before colitis
induction. Other groups received a single i.p. administration of
26106 murine dendritic cells in 100 ml PBS, either untreated (DC
group) or pre-conditioned with Bb-CM (DCBb-CM group) simulta-
neously to TNBS administration. DCs were prepared from bone
marrow dendritic cells (BMDCs) as previously described [14] and
incubated with or without Bb-CM for 18 hours.
Figure 2. Bb preserves the integrity of HT29-19A epithelial cells. Filter-grown HT29-19A monolayers were treated with 10 ng/ml TNFa with
or without live Bb placed in the apical compartment for 4 h. As index of epithelial viability, we measured markers of apoptosis (M30) and epithelial
tight junction integrity (ZO-1). After 4 hour-treatment with Bb, HT29-19A monolayers (CostarH clear 3460) were labelled with the monoclonal
antibody M30 CytoDEATH recognizing caspase-cleaved cytokeratin 18 (1:10, Roche Diagnostics) and rabbit polyclonal anti-ZO-1 (24 mg/ml, Zymed).
Cells were observed with the laser scanning confocal microscope LSM 510 Carl Zeiss. Treatment with H2O2 (100 mM), used as a positive control,
induced apoptosis (blue M30 labeling) and alteration of ZO-1 distribution (green). In contrast, in basal condition or after treatment with Bb at MOI
100, no M30 labeling was observed and ZO-1 distribution was preserved. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0005184.g002
Probiotics and Cell Signaling
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Animals were sacrificed 48 h after TNBS administration and
macroscopic colonic damage was analyzed using the Wallace scoring
method [15]. Protection observed with the various treatments was
calculated taking theWallace scoreofTNBSmice (control) as thehigest
(100%)colonicdamage.TotalRNAwasisolatedfromcolontissueusing
the RNeasy kit (Qiagen). Reverse transcription was performed on
2 mg, followed by real-time PCR (7300 PCR system from
Applied Biosystems) using the Taq-Man PCR Master Mix
(Applied Biosystems) and primers and probes designed by
Applied Biosystems for murine IL-1b, TNF-a, CXCL1 (KC),
COX-2, IL-6, IL-23 and IL-17 and TATA-box binding protein
(Tbp). Data were normalized to expression of Tbp.
Statistical analysis
Statistical analysis was performed using the SAS package. The
results are expressed as scatter plots with medians, or as
means6SEM. Differences between groups were compared by
paired t-test or non-parametric tests (Wilcoxon) and were
considered significant for values of p,0.05.
Results
Bb soluble factors inhibit secretion of inflammatory
cytokines by intestinal epithelial cells
Bb soluble factors inhibit LPS-induced TNFa secretion in
immune cells [11]. Their effect on TNFa-induced cytokine
secretion in HT29-19A epithelial cells was tested using RaybioH
membranes that allow screening of a large panel of inflammatory
factors. Bb and Bb-CM inhibited TNFa-induced secretion of
CXCL8 (IL-8), CXCL1 (GRO) and CCL4 (MIP-1b) and to a
lesser extent of tissue inhibitor of metalloproteinases (TIMP-1,
TIMP-2), neutrophil activating factor-2 (NAP-2), neurotrophin
Figure 3. Bb and its soluble factors inhibit TNFa-induced NF-kB in epithelial cells. A. HT29-19A cells were incubated for 30 min with
TNFa6Bb-CM and localization of the NF-kB p65 subunit was observed by confocal microscopy. Following exposure to TNFa, p65 (green) was
translocated into the nuclei (blue) and co-localization was observed (white spots). Bb-CM inhibited TNFa-induced p65 subunit translocation. n = 3
independent experiments. B. HT29-19A cells were incubated for 4 hours with TNFa6Bb-CM. Electrophoretic migration shift assay (EMSA) was
performed following extraction of nuclear proteins. TNFa condition was taken as 100% activation and Bb-CM induced a 40% inhibition of NF-kB
activation (n = 2 independent experiments). C. Epithelial cells were incubated with TNFa6Bb at MOI 100. Activation of NF-kB was inhibited by ,40%
with Bb but not with commensal bacteria B.breve ATCC 15698, L.rhamnosus 10863, E.rectale L15. n = 2 independent experiments. D. HT29-19A cells
were treated with TNFa6Bb-CM. Total proteins were separated by SDS-PAGE and revealed with antibodies to phospho-IkB-a, IkBa and b-actin. Bb-
CM inhibited the TNFa-induced phosphorylation of IkB-a as early as 5 min and IkB-a degradation after 15 min. n = 3 independent experiments.
doi:10.1371/journal.pone.0005184.g003
Probiotics and Cell Signaling
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NT-3 and growth factors such as hepatocyte growth factor (HGF)
(Fig. 1A). Importantly, Bb and Bb-CM alone did not modify the
cytokine profile observed under basal conditions (data not shown).
TNFa-induced secretion of CXCL8, tested by ELISA, increased
with time but a constant fraction (50 to 58%) was inhibited by Bb-
CM (1282.56211 vs 611.56282 pg/ml after 2 hours, 26956555
vs 11346342 pg/ml after 4 hours, p,0.01; and 42546922 vs
21596227 pg/ml after 7 hours; p,0.01) (Fig. 1B). Notably, Bb-
CM also inhibited IL-1b-induced CXCL8 secretion (data not
shown).
We next evaluated the capacity of apically applied Bb to inhibit
TNFa-induced CXCL8 production in the basolateral compart-
ment of polarized HT29-19A epithelial cells. Basal secretion of
CXCL8 was not modified by Bb (data not shown), but Bb induced
a dose-dependent inhibition of TNFa-induced CXCL8 secretion
that was maximal at MOI 100 (73% inhibition, p,0.0001)
(Fig. 1C). In contrast, no inhibition was observed with the other
tested Gram (+) bacteria (Fig. 1D).
The inhibitory effects of Bb on chemokine secretion were not
due to the alteration of HT29-19A epithelial integrity as attested
by stable electrical resistance of epithelial monolayers in the
presence of bacteria at high concentration (MOI 100, R= 98611
ohms.cm2) as compared to control epithelial cells
(R= 11669 V.cm2). In addition, integrity of tight junctions was
also attested by a normal distribution of ZO-1 protein and by the
lack of bacteria-induced apoptosis of epithelial cells (Fig. 2).
Bb soluble factors inhibit the NF-kB pathway
Bb-CM inhibited TNFa-induced nuclear translocation of
the p65 NF-kB subunit. Nuclear translocation was observed
in 83% of cells activated by TNFa alone, but in only 30% of
cells preincubated with Bb-CM (Fig. 3A). Accordingly Bb soluble
factors impaired the formation of p65- and p50-DNA complexes
in response to a 4-hour stimulation with TNFa (Fig. 3B).
In contrast to Bb (MOI 100), which inhibited by 40% the
formation of the DNA complexes (Fig. 3C), other Gram (+)
bacteria had no effect. Neither Bb nor other Gram (+) bacteria per
se induced the binding of p65- and p50-NF-kB on epithelial DNA.
As shown in Fig. 3D, Bb-CM also reduced the early phosphor-
ylation of IkB-a (5 min) induced by TNFa 2 a step that otherwise
commits the molecule to subsequent ubiquitination and degrada-
tion2 and accordingly promoted stabilization of IkB-a from 15 to
30 min.
Bb soluble factors inhibit the AP-1 pathway
DNA binding of AP-1 induced by TNFa was inhibited by 35%
in the presence of Bb-CM (Fig. 4A) and by 40% by Bb at MOI 100
(Fig. 4B). In contrast to Bb, none of the tested Gram (+) bacteria
had any inhibitory effect (Fig. 4C). Furthermore, Bb-CM inhibited
p38-MAPK phosphorylation, an important step in AP-1 activation
(Fig. 4D). This inhibition, observed at 15 min (- 44%), was still
visible after 30 min (- 63%).
Figure 4. Bb and its soluble factors inhibit TNFa-induced phosphorylation of p38-MAPK in epithelial cells. A–C. HT29-19A cells were
incubated for 4 hours on the apical surface with live Bb or commensal bacteria B.breve ATCC 15698, L.rhamnosus 10863, E.rectale L15 at MOI 100,
together with basolateral TNFa. Activation of AP-1 assessed by EMSA was inhibited by,35% in the presence of Bb-CM and by,40% in the presence
of Bb, but not in the presence of other bacteria. n = 2 independent experiments. D. HT29-19A cells were treated with TNFa6Bb-CM. Total proteins
were analysed by SDS-PAGE and revealed with antibodies to phospho-p38-MAPK, p38-MAPK and b-actin. Bb-CM inhibited TNFa-induced
phosphorylation of p38-MAPK from 15 to 30 min of incubation. n = 3 independent experiments.
doi:10.1371/journal.pone.0005184.g004
Probiotics and Cell Signaling
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Bb soluble factors alleviate inflammation in a murine
model of TNBS colitis
We next investigated the capacity of Bb soluble factors to
dampen the colonic inflammatory response in TNBS-induced
colitis in mice. The high inflammatory score observed in control
TNBS mice, (Wallace score WS=4.560.4) was decreased in Bb
i.g. mice (WS to 3.260.8), indicating a mild protection (30%)
(Fig. 5A, 5B). Accordingly, high mRNA expression of pro-
inflammatory cytokines/mediators observed in control TNBS
mice slightly decreased in Bb i.g. mice (Fig. 5C). In contrast, pre-
treatment with Bb-CM by i.p. route induced a significant
protection against colitis (WS= 1.760.8, 62% protection) and a
statistically significant decrease in pro-inflammatory cytokine
expression [IL-1b, CXCL1 (equivalent to human IL-8), COX2,
IL-23, IL-6]. Since i.p. administration of Bb-CM was efficient in
dampening inflammation, the effect of soluble factors on mucosal
dendritic cells (DC) was tested. DC pre-conditioned with Bb-CM
(DCBb-CM) were injected i.p. into mice at the same time as TNBS
challenge. In contrast to non-treated DC (WS=4.460.4), DCBb-
CM conferred a significant protection against colitis
(WS= 2.360.4, 49% protection, p,0.01) and reduced the
expression of all pro-inflammatory cytokines/mediators. These
results indicate a protective effect of Bb soluble factors in vivo and
suggest that this protective effect relies primarily on their capacity
to condition regulatory dendritic cells.
Discussion
Selected strains of probiotic micro-organisms participate in the
control of intestinal homeostasis and help preventing intestinal
Figure 5. Protective effect of Bb and Bb-CM in TNBS-induced colitis in mice. A. Wallace scores were used to semi-quantify colitis activity in
BALB/c mice after colonic instillation of TNBS (control group) with or without intragastric pre-treatment with 108 CFU Bb (Bb i.g.), intraperitoneal
injection of Bb-CM (Bb-CM i.p.), intraperitoneal injection of non treated-DC (DC) or Bb-CM conditioned-DC (DCBb-CM). The mild inhibition of colitis
observed with Bb i.g. became significant with Bb-CM and DCBb-CM. B. Percentage protection in mice of the different groups compared to control
(TNBS only). C. Quantitative RT-PCR analysis of mRNA expression of pro-inflammatory cytokines/mediators in the colon, 48 hours after TNBS-induced
colitis with or without treatment. A significant inhibition of pro-inflammatory molecules in colonic mucosa (IL-1b, CXCL-1, IL-23, IL-6, COX2) was
observed in the presence of Bb-CM or Bb-CM pre-conditioned DC. Scatter plots are presented with medians. *p,0.05, {p,0.01 vs TNBS; n = 7 to 8
mice per group.
doi:10.1371/journal.pone.0005184.g005
Probiotics and Cell Signaling
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disorders. In the intestinal microflora, Bifidobacterium species
are generally considered beneficial to the host and various
strains of bifidobacteria are used as probiotics. The mechanisms
by which these bacteria can modulate the function of epithelial
and immune cells remain incompletely elucidated. We have
previously shown that soluble factors from Bifidobacterium breve C50
decrease pro-inflammatory cytokine secretion by immune cells
[11]. We now show that these soluble factors effectively dampen
intestinal inflammation by targeting both epithelial and local
dendritic cells.
In inflammatory conditions, an important function of intestinal
epithelial cells is to control the influx and activation of immune
cells into the lamina propria through the production of chemokines
and cytokines. Previous studies have supported the view that
selected commensal or probiotic bacteria can alleviate inflamma-
tion [16]. Along this line, we have already demonstrated that the
low molecular weight soluble factors (,3 kD) produced by Bb
inhibit LPS-induced TNFa secretion by immune cells [11]. In this
study, Bb and Bb-CM, unlike other tested Gram (+) bacteria, were
able to inhibit the release of chemokines and various inflammatory
molecules in epithelial cells. The most prominent effect of Bb-CM
was observed on CXCL8 secretion. Inhibition of CXCL8
secretion by probiotics has been reported in epithelial cells but
the relative importance of whole bacteria versus soluble factors have
remained elusive [17,18]. Different steps along the NF-kB
pathway were targeted according to bacterial strains tested.
Commensal Salmonella[9] or Lactobacillus casei[10] could inhibit
p65 nuclear translocation through a decrease in IkB-a ubiquitina-
tion and degradation, B. thetaiotaomicron commensal bacteria
promoted the nuclear export of RelA and PPAR-c[19] while
VSL#3 inhibited proteasome degrading activity[20] without
altering IkB-a phosphorylation. Our study indicates that both
pathways implicated in CXCL8 expression, NF-kB and AP-1 [21],
are targeted by Bb soluble factors. Interestingly, Bb inhibited key
early phosphorylation steps in these two distinct signaling
cascades. These results suggest that as yet unknown soluble
factor(s) present in the low molecular weight active fraction of Bb-
CM interfere with serine-threonine kinases and cellular phosphor-
ylation. The nature of this(ese) factor(s) is not yet elucidated.
Previous studies [11] underlined that inhibition of LPS-induced
TNFa-release in immune cells by Bb C50 was heat-resistant, was
not related to short-chain fatty acids (butyrate or lactate) and that
pepsin-trypsin- or proteinase K- treated CM still retained an
inhibitory effect ([11] and unpublished result). Additional
unpublished studies indicated that DNAse I treatment of CM or
the use of immune cells from TLR92/2mice[22] did not point to
the role of TLR9 ligands as active component(s) of Bb-CM. Studies
aiming to characterize the active factors by differential mass
spectrometry of active and inactive Bifidobacterium strains (Bb
C50 and Bb ATCC 15698) are in progress and may help gaining
further mechanistic insight.
To assess whether in vitro observations could be validated in vivo,
we used a mouse model of colitis. Significant protection was
observed after pre-treatment by i.p. injection of Bb soluble
factors. Similar protection was obtained after adoptive transfer
of dendritic cells pre-treated with Bb-conditioned medium. These
results are coherent with our previous in vitro results in immune
cells[11] and indicate that Bb-derived soluble factors can exert in
vivo anti-inflammatory effects through interaction with local
immune cells, as also reported with selected strains of lactic acid
bacteria [14]. When Bb was administered intragastrically, a milder
protection was observed, suggesting that the anti-inflammatory
properties of Bb require the release of sufficient amounts of soluble
factors in situ, in the vicinity of colonic mucosa. In our
previous study, the inhibitory capacity of soluble factors on
immune cells was maintained after crossing an epithelial cell
monolayer. However the stability of these factors in the intestinal
lumen may be insufficient to allow their delivery to the colonic
mucosa. This hypothesis is in keeping with the observation that
protection by probiotics is often more effective in the proximal
intestine (rotavirus diarrhea) than in the colon (inflammatory
bowel diseases). In this respect, it is interesting that Fecalibacterium
prausnitzii, a commensal strain poorly represented in the microbi-
ota of patients with Crohn’s disease, can produce soluble anti-
inflammatory factors which may thus be delivered directly to the
adjacent mucosa [23].
Taken together, our results indicate that small soluble
factors released by Bifidobacterium breve C50 might help maintain
intestinal homeostasis by targeting cells of the innate immune
system such as epithelial and dendritic cells. Studies are needed to
further characterize the Bb soluble factor(s) responsible for the
inhibition of kinases involved in multiple steps of intestinal
inflammation.
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